Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 3/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5478436 | 1.00 | IRAK4 (0.43) | IRAK4MGLLOPRM1CYP2D6GPR119 | |
| SCHEMBL5478432 | 1.00 | IRAK4 (0.43) | IRAK4MGLLOPRM1CYP2D6GPR119 | |
| SCHEMBL4878236 | 0.89 | KMT2A (0.52) | IRAK4MGLLCYP2D6HRH3 | |
| SCHEMBL4878245 | 0.89 | KMT2A (0.52) | IRAK4MGLLCYP2D6HRH3 | |
| SCHEMBL4878243 | 0.89 | KMT2A (0.52) | IRAK4MGLLCYP2D6HRH3 | |
| SCHEMBL20066225 | 0.85 | CYP2D6 (0.47) | IRAK4OPRM1CYP2D6GPR119HRH3 | |
| SCHEMBL5473403 | 0.85 | YAP1 (0.45) | IRAK4MGLLOPRM1GPR119OPRD1 | |
| SCHEMBL5473628 | 0.85 | YAP1 (0.45) | IRAK4MGLLOPRM1GPR119OPRD1 | |
| SCHEMBL5473407 | 0.85 | YAP1 (0.45) | IRAK4MGLLOPRM1GPR119OPRD1 | |
| SCHEMBL5466310 | 0.84 | CYP2D6 (0.45) | MGLLOPRM1CYP2D6HRH3OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078120-A1 | Novel piperidine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1679069-A1 | NOVEL PIPERIDINE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078120-A1 | Novel piperidine derivative | LDLR, PRMT5, MSR1 | IRAK4 383/4885MGLL 1254/4885OPRM1 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.